La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Myriad Genetics Gestione

Gestione criteri di controllo 2/4

Myriad Genetics' Il CEO è Paul Diaz, nominato in Aug2020, e ha un mandato di 4.08 anni. la retribuzione annua totale è $ 12.11M, composta da 9% di stipendio e 91% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.47% delle azioni della società, per un valore di € 11.01M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 4.6 anni.

Informazioni chiave

Paul Diaz

Amministratore delegato

US$12.1m

Compenso totale

Percentuale dello stipendio del CEO	9.0%
Mandato del CEO	4.2yrs
Proprietà del CEO	0.4%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	4.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Diaz rispetto agli utili di Myriad Genetics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$155m
Mar 31 2024	n/a	n/a	-US$235m
Dec 31 2023	US$12m	US$1m	-US$263m
Sep 30 2023	n/a	n/a	-US$274m
Jun 30 2023	n/a	n/a	-US$248m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$11m	US$1m	-US$112m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$13m	US$1m	-US$27m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$97m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$16m	US$383k	-US$224m

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 12.11M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 2.49M ).

Compensazione vs guadagni: La retribuzione di Paul è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Paul Diaz (62 yo)

4.2yrs

Mandato

US$12,108,359

Compensazione

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Diaz	CEO, President & Director	4.2yrs	US$12.11m	0.44% € 8.6m
Samraat Raha	Chief Operating Officer	less than a year	US$5.02m	Nessun dato
Dale Muzzey	Chief Scientific Officer	2.8yrs	US$2.23m	0.12% € 2.3m
Mark Verratti	Chief Commercial Officer	7.2yrs	US$2.88m	0.32% € 6.2m
Scott Leffler	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Natalie Munk	Principal Accounting Officer	2.3yrs	Nessun dato	0.048% € 931.4k
Kevin Haas	Chief Technology Officer	3.7yrs	US$1.64m	0.14% € 2.8m
Matthew Scalo	Senior Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Jennifer Fox	Chief Legal Officer	less than a year	Nessun dato	Nessun dato
Glenn Farrell	Senior VP & Chief Marketing Officer	1.8yrs	Nessun dato	Nessun dato
Shereen Solaiman	Chief People Officer	1.6yrs	Nessun dato	0.0031% € 61.4k
Patrick Burke	Executive Vice President of Strategy & Innovation	3.4yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di MYD è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Diaz	CEO, President & Director	4.2yrs	US$12.11m	0.44% € 8.6m
Paul Bisaro	Independent Director	2yrs	US$258.48k	0.027% € 526.4k
Lee Newcomer	Independent Director	5.1yrs	US$447.99k	0.073% € 1.4m
Daniel Skovronsky	Independent Director	4.3yrs	US$433.49k	0.077% € 1.5m
Colleen Reitan	Independent Director	5.1yrs	US$443.49k	0.030% € 577.8k
Heinrich Dreismann	Independent Director	14.3yrs	US$443.49k	0.12% € 2.3m
S. Phanstiel	Independent Chair of the Board	15.1yrs	US$563.49k	0.16% € 3.1m
Rashmi Kumar	Independent Director	4.1yrs	US$433.49k	0.068% € 1.3m

4.7yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MYD sono considerati esperti (durata media dell'incarico 4.5 anni).

Myriad Genetics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Recent updates

Now 22% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Second quarter 2024 earnings released: US$0.41 loss per share (vs US$1.42 loss in 2Q 2023)

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Financial position

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023)

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022)

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021)

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021)

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.061 loss in 2Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Myriad Genetics, Inc. Announces Executive Changes

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.52 loss in 1Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

High number of new directors

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

Forecast to breakeven in 2024

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Myriad Genetics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Independent Chair of the Board recently sold €529k worth of stock